Cheiljedang Corp.

Cj Cheiljedang Corporation

Ji-Sook Park

Ki-Wan Kim

Dong-Eok Lee

Myung-Suk Oh

Bo-Sup Chung

Byung-Jhip Ha

Myung-suk Oh

Bo-sup Chung

Jee-Won Ahn

Jong-Sang Chung

Hyung-Ki Park

The present invention relates to a fusion protein in which a carboxy terminal of human erythropoietin (EPO) is fused with a carboxy terminal peptide fragment of &#x3b2; subunit of human chorionic gonadotropin (HCG), to DNA encoding the fusion protein, and to a method for preparation of the fusion protein. The fusion protein has the enhanced in vivo activity of erythropoietin.

Fusion protein having the enhanced in vivo activity of erythropoietin

The present invention relates to a fusion protein having enhanced in vivo activity of erythropoietin wherein a carboxy terminal peptide fragment of thrombopoietin is fused with the carboxy terminal of human erythropoietin. This fusion protein has highly enhanced in vivo half-life due to increased carbohydrate content without loss of the inherent activity of erythropoietin, and does not cause any antigenicity when applied to the human body.

Fusion protein having enhanced in vivo activity of erythropoietin

Provided is a fusion protein comprising, at its carboxy terminal of human erythropoietin (EPO), a mutant having one to four amino acid substitutions in the carboxy terminal peptide (CTP) fragment of a human chorionic gonadotropin (HCG) &#x3b2; subunit, for increasing an in vivo half-life activity of EPO. The in vivo half-life can be greatly elongated while retaining the intrinsic activity of the EPO, without increasing the sugar chain content.

Fusion protein having enhanced in vivo erythropoietin activity

Growing community of inventors

Seoul, South Korea

Ji-Sook Park